December 26, 2025 - 23:18

In the premarket trading session, shares of Nvidia experienced a modest increase following the announcement of a licensing agreement with the artificial intelligence startup Groq. This partnership is expected to bolster Nvidia's position in the rapidly growing AI sector, reflecting investor confidence in the company's strategic direction.
Conversely, shares of Indian technology services provider Coforge Ltd. faced a decline ahead of the US market opening. This drop comes after the company revealed plans to acquire Encora for an enterprise value of $2.35 billion in an all-stock transaction. Investors are likely weighing the implications of this significant investment on Coforge's future performance.
Meanwhile, Biohaven Pharmaceuticals saw its shares plummet by as much as 14 percent in premarket trading. This decline followed disappointing results from a mid-stage study of its experimental drug BHV-7000, which aimed to treat major depressive disorder. The drug failed to meet its primary endpoint, although some positive trends were noted in specific subgroups of participants, raising questions about the drug's overall efficacy.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...